Clinical Trial

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-10-24; most recent amendment 2026-03-31.
Trial Details
NCT Number NCT07221656
Lead Sponsor Mayo Clinic
Conditions Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Enrollment 20 participants
Start Date 2027-02-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-02